|
1
|
Siddiqui S, Ali MU, Ali MA, Shah N and
Nasreen S: Lung carcinoma: Its profile and changing trends. J Ayub
Med Coll Abbottabad. 22:116–119. 2010.PubMed/NCBI
|
|
2
|
Suzuki H, Takahashi T, Kuroishi T, Suyama
M, Ariyoshi Y, Takahashi T and Ueda R: p53 mutations in non-small
cell lung cancer in Japan: Association between mutations and
smoking. Cancer Res. 52:734–736. 1992.PubMed/NCBI
|
|
3
|
Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu
N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, et
al: Prognostic and predictive importance of p53 and RAS for
adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol.
25:5240–5247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mayo LD, Dixon JE, Durden DL, Tonks NK and
Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells
to chemotherapy. J Biol Chem. 277:5484–5489. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Agarwal ML, Taylor WR, Chernov MV,
Chernova OB and Stark GR: The p53 network. J Biol Chem. 273:1–4.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Müller I, Niethammer D and Bruchelt G:
Anthracycline-derived chemotherapeutics in apoptosis and free
radical cytotoxicity (Review). Int J Mol Med. 1:491–494.
1998.PubMed/NCBI
|
|
8
|
Zhu T, Li LL, Xiao GF, Luo QZ, Liu QZ, Yao
KT and Xiao GH: Berberine increases doxorubicin sensitivity by
suppressing STAT3 in lung cancer. Am J Chin Med. 43:1487–1502.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li ZL, Chen C, Yang Y, Wang C, Yang T,
Yang X and Liu SC: Gamma secretase inhibitor enhances sensitivity
to doxorubicin in MDA-MB-231 cells. Int J Clin Exp Pathol.
8:4378–4387. 2015.PubMed/NCBI
|
|
10
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watkins SK, Egilmez NK, Suttles J and
Stout RD: IL-12 rapidly alters the functional profile of
tumor-associated and tumor-infiltrating macrophages in vitro and in
vivo. J Immunol. 178:1357–1362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martinez FO, Gordon S, Locati M and
Mantovani A: Transcriptional profiling of the human
monocyte-to-macrophage differentiation and polarization: New
molecules and patterns of gene expression. J Immunol.
177:7303–7311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mills CD: M1 and M2 macrophages: Oracles
of health and disease. Crit Rev Immunol. 32:463–488. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martinez FO and Gordon S: The M1 and M2
paradigm of macrophage activation: Time for reassessment.
F1000Prime Rep. 6:132014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitchem JB, Brennan DJ, Knolhoff BL, Belt
BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L,
Piwnica-Worms D, et al: Targeting tumor-infiltrating macrophages
decreases tumor-initiating cells, relieves immunosuppression, and
improves chemotherapeutic responses. Cancer Res. 73:1128–1141.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gonzalez FJ, Vicioso L, Alvarez M, Sevilla
I, Marques E, Gallego E, Alonso L, Matilla A and Alba E:
Association between VEGF expression in tumour-associated
macrophages and elevated serum VEGF levels in primary colorectal
cancer patients. Cancer Biomark. 3:325–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schoppmann SF, Fenzl A, Nagy K, Unger S,
Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R and Birner P: VEGF-C
expressing tumor-associated macrophages in lymph node positive
breast cancer: Impact on lymphangiogenesis and survival. Surgery.
139:839–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schoppmann SF, Birner P, Stöckl J, Kalt R,
Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K and Kerjaschki
D: Tumor-associated macrophages express lymphatic endothelial
growth factors and are related to peritumoral lymphangiogenesis. Am
J Pathol. 161:947–956. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao X, Ping Y, Liu Y, Chen K, Yoshimura T,
Liu M, Gong W, Chen C, Niu Q, Guo D, et al: Vascular endothelial
growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic
mimicry formation, neovascularization and tumor initiation by
glioma stem-like cells. PLoS One. 8:e571882013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hamerlik P, Lathia JD, Rasmussen R, Wu Q,
Bartkova J, Lee M, Moudry P, Bartek J Jr, Fischer W, Lukas J, et
al: Autocrine VEGF-VEGFR2-neuropilin-1 signaling promotes glioma
stem-like cell viability and tumor growth. J Exp Med. 209:507–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arinaga M, Noguchi T, Takeno S, Chujo M,
Miura T and Uchida Y: Clinical significance of vascular endothelial
growth factor C and vascular endothelial growth factor receptor 3
in patients with nonsmall cell lung carcinoma. Cancer. 97:457–464.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niki T, Iba S, Tokunou M, Yamada T,
Matsuno Y and Hirohashi S: Expression of vascular endothelial
growth factors A B, C, and D and their relationships to lymph node
status in lung adenocarcinoma. Clin Cancer Res. 6:2431–2439.
2000.PubMed/NCBI
|
|
24
|
Timoshenko AV, Rastogi S and Lala PK:
Migration-promoting role of VEGF-C and VEGF-C binding receptors in
human breast cancer cells. Br J Cancer. 97:1090–1098. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee E, Koskimaki JE, Pandey NB and Popel
AS: Inhibition of lymphangiogenesis and angiogenesis in breast
tumor xenografts and lymph nodes by a peptide derived from
transmembrane protein 45A. Neoplasia. 15:112–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roberts N, Kloos B, Cassella M,
Podgrabinska S, Persaud K, Wu Y, Pytowski B and Skobe M: Inhibition
of VEGFR-3 activation with the antagonistic antibody more potently
suppresses lymph node and distant metastases than inactivation of
VEGFR-2. Cancer Res. 66:2650–2657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alam A, Blanc I, Gueguen-Dorbes G, Duclos
O, Bonnin J, Barron P, Laplace M-C, Morin G, Gaujarengues F, Dol F,
et al: SAR131675, a potent and selective VEGFR-3-TK inhibitor with
antilymphangiogenic, antitumoral, and antimetastatic activities.
Mol Cancer Ther. 11:1637–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alitalo AK, Proulx ST, Karaman S,
Aebischer D, Martino S, Jost M, Schneider N, Bry M and Detmar M:
VEGF-C and VEGF-D blockade inhibits inflammatory skin
carcinogenesis. Cancer Res. 73:4212–4221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ostrand-Rosenberg S: Immune surveillance:
A balance between protumor and antitumor immunity. Curr Opin Genet
Dev. 18:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Biswas SK, Allavena P and Mantovani A:
Tumor-associated macrophages: functional diversity, clinical
significance, and open questions. Semin Immunopathol. 35:585–600.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kerjaschki D: The crucial role of
macrophages in lymphangiogenesis. J Clin Invest. 115:2316–2319.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chung ES, Chauhan SK, Jin Y, Nakao S,
Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L and Dana R:
Contribution of macrophages to angiogenesis induced by vascular
endothelial growth factor receptor-3-specific ligands. Am J Pathol.
175:1984–1992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mitsudomi T, Oyama T, Kusano T, Osaki T,
Nakanishi R and Shirakusa T: Mutations of the p53 gene as a
predictor of poor prognosis in patients with non-small-cell lung
cancer. J Natl Cancer Inst. 85:2018–2023. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002.PubMed/NCBI
|
|
36
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Inoue A, Narumi K, Matsubara N, Sugawara
S, Saijo Y, Satoh K and Nukiwa T: Administration of wild-type p53
adenoviral vector synergistically enhances the cytotoxicity of
anti-cancer drugs in human lung cancer cells irrespective of the
status of p53 gene. Cancer Lett. 157:105–112. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dunkern TR, Wedemeyer I, Baumgärtner M,
Fritz G and Kaina B: Resistance of p53 knockout cells to
doxorubicin is related to reduced formation of DNA strand breaks
rather than impaired apoptotic signaling. DNA Repair (Amst).
2:49–60. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng RD, Phillips P and El-Deiry WS:
p53-independent increase in E2F-1 expression enhances the cytotoxic
effects of etoposide and of adriamycin. Int J Oncol. 14:5–14.
1999.PubMed/NCBI
|
|
42
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pan L, Lu J, Wang X, Han L, Zhang Y, Han S
and Huang B: Histone deacetylase inhibitor trichostatin a
potentiates doxorubicin-induced apoptosis by up-regulating PTEN
expression. Cancer. 109:1676–1688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Khromova N, Kopnin P, Rybko V and Kopnin
BP: Downregulation of VEGF-C expression in lung and colon cancer
cells decelerates tumor growth and inhibits metastasis via multiple
mechanisms. Oncogene. 31:1389–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen H, Ding X, Gao Y, Jiang X, Liu X,
Chen Y, Gao J, Zhou X, Cai Z and Sun Q: Inhibition of angiogenesis
by a novel neutralizing antibody targeting human VEGFR-3. Mabs.
5:956–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Albuquerque RJ: The newest member of the
VEGF family. Blood. 121:4015–4016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sallinen H, Anttila M, Narvainen J,
Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma
V-M, Heinonen S, et al: Antiangiogenic gene therapy with soluble
VEGFR-1, −2, and −3 reduces the growth of solid human ovarian
carcinoma in mice. Mol Ther. 17:278–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang H, Kim C, Kim MJ, Schwendener RA,
Alitalo K, Heston W, Kim I, Kim WJ and Koh GY: Soluble vascular
endothelial growth factor receptor-3 suppresses lymphangiogenesis
and lymphatic metastasis in bladder cancer. Mol Cancer. 10:362011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mir O, Brodowicz T, Italiano A, Wallet J,
Blay J-Y, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E,
Salas S, et al: Safety and efficacy of regorafenib in patients with
advanced soft tissue sarcoma (REGOSARC): A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet Oncol.
17:1732–1742. 2016. View Article : Google Scholar : PubMed/NCBI
|
